Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED -0.92%78 Forward PE Ratio is 5.59 as of Aug. 05, 2026. GuruFocus rates XTER:MED with a GF Score™ of 78/100 and a GF Value™ of €3.03 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 313 Healthcare Providers & Services companies, MediClin AG ranks better than 96.17% on this metric.
MediClin AG (XTER:MED) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
MediClin AG Forward PE Ratio Related Terms
MediClin AG Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for MediClin AG's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediClin AG Forward PE Ratio Chart
MediClin AG Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
6.21
4.81
MediClin AG Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
6.21
6.24
4.83
5.57
4.81
4.89
XTER:MED vs HCA, THC, DVA: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, MediClin AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where MediClin AG's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
MediClin AG (XTER:MED) has a Forward PE Ratio of 5.59 as of Aug. 05, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MediClin AG and its competitors. According to the industry distribution chart, MediClin AG ranks #12 out of 313 companies in the Healthcare Providers & Services industry, placing it in the top 3.8%.
Is MediClin AG's Forward PE Ratio too high?
MediClin AG's current Forward PE Ratio is 5.59. The Healthcare Providers & Services industry median Forward PE Ratio is 18.40. MediClin AG's value of 5.59 is 69.6% below this industry median. Based on the distribution chart, MediClin AG ranks #12 out of 313 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, MediClin AG has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's Forward PE Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #12 out of 313 companies for Forward PE Ratio. This places MediClin AG in the top 4% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 18.40. MediClin AG's value of 5.59 is 69.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.40, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current Forward PE Ratio of 5.59 is 69.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current Forward PE Ratio is 5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.03, compared to a current price of €4.32 — trading 42.6% above its estimated fair value. The current Forward PE Ratio is 5.59 and 69.6% below the Healthcare Providers & Services industry median of 18.40. MediClin AG's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current Forward PE Ratio is 5.59 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €4.32 is trading 42.6% above its estimated GF Value™ of €3.03.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
Forward PE Ratio: 5.59
GF Value™: €3.03 vs. price of €4.32 (42.6% above fair value)
Industry Position: 69.6% below the Healthcare Providers & Services median (#12 of 313)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
78GF Score
Get the complete analysis for XTER:MED
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
